Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Nvs - Caught on Camera

Is This Pharmaceutical Giant a Winning Tariff-Proof Stock to Buy for 2026?

Novartis (NVS) is trading at new all-time highs on Monday. Shares are up nearly 50% over the past 52 weeks. NVS maintains a 100% “Buy” technical opinion from Barchart. Novartis has benefitted in recent days from its CEO’s comments that the company will have essentially limited tariff exposure by mid-2026....

Barchart

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts

Novartis AG (NYSE:NVS) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well into the next decade.

Benzinga

Novartis Maintains Outlook Even As Generics Bite Into Profits

Swiss pharmaceutical major Novartis AG (NYSE:NVS) reported third-quarter 2025 results on Tuesday, reaffirming its full-year guidance as strong sales from key growth drugs offset mounting generic competition in the U.S.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain

Novartis AG (NYSE:NVS) on Wednesday shared topline data from the Phase 3 REPLENISH trial of Cosentyx in patients with polymyalgia rheumatica.

Benzinga

Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial

On Friday, Novartis AG (NYSE:NVS) shared results from the five-year analysis of the Phase 3 NATALEE trial of Kisqali (ribociclib).

Benzinga

Novartis Strengthens Kidney Disease Pipeline With Promising Data

Novartis A/S (NYSE:NVS) on Thursday shared final results from the APPLAUSE-IgAN Phase 3 study evaluating Fabhalta (iptacopan) in adults with IgA nephropathy (IgAN).

Benzinga

Novartis Builds US Drug Reserves Against Potential Tariffs

Novartis AG (NYSE:NVS) has reportedly built up its pharmaceutical stockpiles in the U.S. as a cushion against the potential impact of tariffs under consideration by the Trump administration, chief executive Vas Narasimhan said in a recent interview.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver

Novartis is betting big on radioligand cancer therapy, but while the long-term growth story looks strong, NVS stock may face a short-term pullback

MarketBeat

Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition

Tourmaline Bio, Inc. (NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of cardiovascular and kidney treatments.

Benzinga

Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook

Weaker prospects for pharmaceutical giant Novo Nordisk A/S (NYSE:NVS) have prompted Denmark's economic ministry to cut its 2025 GDP forecast, now expecting just 1.4% growth, down 1.5 percentage points from May's projection.

Benzinga

Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder

Novartis AG (NYSE:NVS) released topline results on Tuesday from the VAYHIT2 Phase 3 trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids.

Benzinga

Novartis' Investigational Drug Aces Two Pivotal Trials For Chronic Disease Impacting Tears, Saliva

Novartis AG (NYSE:NVS) on Monday released topline data from two Phase 3 trials, NEPTUNUS-1 and NEPTUNUS-2, evaluating ianalumab (VAY736) in adults with active Sjögren’s disease.

Benzinga

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs

On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in the US are made abroad, a statistic the President wants to flip on its head.

Benzinga

Novartis Raises Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback (CORRECTED)

Editor’s Note: The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” mentioned in the original title.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI), propelling the industry’s growth. Amid this backdrop, quality medical stocks Pfizer (PFE), AstraZeneca (AZN), and Novartis (NVS), which are transforming medicine with AI-powered drug discovery, could be ideal portfolio additions. Continue reading.

StockNews.com

3 Gene Therapy Stocks With Game-Changing Potential

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, investing in gene therapy stocks like Pfizer (PFE), Sanofi (SNY), and Novartis AG (NVS) could be beneficial. Read on….

StockNews.com

3 European Stocks to Watch as the EU Economy Strengthens

With inflation dropping to 2.2% in August 2024 and the potential for further interest rate cuts on the horizon, European markets could become more attractive as growth picks up. Thus, one could consider keeping an eye on fundamentally sound European stocks like Novartis (NVS), Unilever (UL), and Siemens Aktiengesellschaft (SIEGY).…

StockNews.com

3 High-Dividend Pharma Blue Chips That Are on Sale Right Now

With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the market. Amid this backdrop, it could be wise to scoop up the shares of fundamentally sound pharma stocks like AbbVie (ABBV), Novartis (NVS), and Pfizer (PFE), which are not just…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 European Stocks to Buy as the Continent’s Economy Recovers

As Europe navigates a complex landscape of slowing inflation, stable employment, and modest GDP growth, it may be an opportune time for investors to consider investing in quality stocks like Novo Nordisk (NVO), SAP SE (SAP), and Novartis (NVS), which are poised to capitalize on the continent’s recovery. Read on….

Barchart

Chart of the Day: Novartis - Take Another Look

The Chart of the Day belongs to the Swiss pharmaceutical company Novartis (NVS) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

StockNews.com

4 Pharma Titans Making Waves in Wall Street

The pharma industry is well-positioned to remain buoyed, owing to the rise in chronic diseases, a growing elderly population, and the integration of advanced technologies. Given this backdrop, quality pharma stocks Bristol-Myers Squibb Company (BMY), Johnson & Johnson (JNJ), Novartis AG (NVS), and Merck & Co. (MRK), making waves in…

StockNews.com

4 Sky-Rocketing Pharma Stocks to Watch

The pharmaceutical industry is experiencing significant growth due to the rising demand for quality healthcare and high-quality drugs. This surge is further supported by the rapid growth in the global elderly population and the increase in chronic illnesses. Therefore, investors could consider adding pharma stocks Spero Therapeutics (SPRO), Wave Life…

StockNews.com

3 B-Rated Pharma Stocks to Secure Now With Great Value

The pharmaceutical industry, which experienced significant growth over the past years, is anticipated to remain buoyed, driven by the increasing prevalence of chronic diseases, advancements in medical technology, and rising healthcare awareness and expenditure. Given this backdrop, quality pharma stocks Voyager Therapeutics (VYGR), Sanofi (SNY), and Pacira BioSciences (PCRX), with…

StockNews.com

Top 3 Pharma Stocks With Bullish Momentum

The pharmaceutical industry’s future appears increasingly optimistic, encouraged by surging healthcare spending due to the rise of chronic and rare disease incidences and an expanding elderly population. The encouraging prognosis of the industry is further bolstered by unwavering ventures into research and development structures and technological advancements. Given this backdrop,…

StockNews.com

Will These 3 Pharma Stocks Become Gainers in 2024?

The pharmaceutical sector is anticipated to prosper due to the strong demand for drugs and therapies and the adoption of advanced technologies. So, let’s analyze whether pharmaceutical stocks Kamada (KMDA), Neurocrine Biosciences (NBIX), and Novartis (NVS) are well positioned to capitalize on the industry’s growth prospects.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.